X
API Suppliers
US DMFs Filed
CEP/COS Certifications
JDMFs Filed
Other Certificates
Other Suppliers
USA (Orange Book)
Europe
Canada
Australia
South Africa
Uploaded Dossiers
U.S. Medicaid
Annual Reports
https://www.pharmacompass.com/pdf/news/enforcement-report-week-of-december-6-2023-46648.pdf
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=204470
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=215776
https://www.newswire.ca/news-releases/labelling-update-regarding-the-use-of-non-steroidal-anti-inflammatory-drugs-nsaids-beyond-20-weeks-of-pregnancy-and-risk-of-kidney-damage-to-unborn-babies-866562162.html
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=211910
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=212705
https://www.moneycontrol.com/news/business/lupin-launches-generic-arthritis-relief-tablet-in-us-5005841.html
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=212517
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=204920
https://www.usatoday.com/story/opinion/2019/01/12/why-fda-doesnt-always-catch-tainted-medicines/2538786002/
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=204206
https://endpts.com/astrazeneca-hands-over-some-rights-to-nexium-vimovo-to-grunenthal-as-its-plots-turnaround/
https://www.genengnews.com/news/grunenthal-acquires-partial-rights-to-nexium-vimovo-from-astrazeneca-for-up-to-922m/
https://globenewswire.com/news-release/2018/09/27/1576930/0/en/Nicox-and-Fera-Pharmaceuticals-to-Focus-on-a-Rare-Disease-Indication-for-Naproxcinod.html
https://www.reuters.com/article/us-health-heart-diclofenac/common-painkiller-tied-to-increased-risk-of-heart-problems-idUSKCN1M12CD?feedType=RSS&feedName=healthNews
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=202461
https://www.fiercebiotech.com/antibe-builds-case-for-gi-safety-naproxen-alternative
https://www.biospace.com/article/releases/antibe-therapeutics-announces-successful-phase-2b-gastrointestinal-safety-study-for-lead-pain-drug-atb-346/
https://www.reuters.com/article/us-health-nsaids-overdosing/many-people-take-dangerously-high-amounts-of-ibuprofen-idUSKBN1FS336
https://www.fiercepharma.com/pharma/specialty-pharmacy-scrutiny-hits-again-state-s-focus-horizon-meds
http://www.wsj.com/articles/study-suggests-celebrex-isnt-riskier-than-rival-pain-drugs-1479073501
http://www.reuters.com/article/us-health-nsaids-heart-failure-idUSKCN12K2J1
http://www.pharma-excipients.ch/2016/03/03/novel-naproxen-esomeprazole-magnesium-compound-pellets-based-on-acid-independent-mechanism-in-vitro-and-in-vivo-evaluation/
http://www.fiercepharmamarketing.com/press-releases/ready-enter-partnering-discussions-key-oxpzero-nsaids
http://www.fiercepharma.com/story/big-pharmas-steady-double-digit-price-hikes-cost-medicare-billions/2015-12-22
http://www.forbes.com/sites/johnlamattina/2015/09/02/uk-study-indicates-that-the-cardiovascular-risk-of-celebrex-no-different-from-other-pain-drugs/
http://www.fiercepharma.com/story/heres-ma-strategy-buy-products-hike-prices-watch-sales-grow/2015-04-27
http://www.fiercepharma.com/story/pernix-figures-1-1-1-equals-more-three-new-zohydro-salesforce/2015-03-18
http://www.prnewswire.com/news-releases/nanosphere-health-sciences-announces-patent-pending-status-for-nanoparticle-encapsulation-of-nsaids-300019412.html
http://ir.horizon-pharma.com/news-releases/news-release-details/horizon-pharma-plc-files-patent-infringement-lawsuit-against
Market Place
Share 
